drugset / Trial / NCT00150982

Alefacept Mechanism of Action in Psoriasis

NCT00150982

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine the mechanism of action of alefacept in patients with psoriasis.

Timeline

Start
2003-09
Primary completion
Completion
2005-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Alefacept Protein / enzyme biologic 7.5 mg Intravenous

Indications